aod9604 peptide benefits side effects AOD-9604 Safety Profile: What Clinical Trials Show AOD 9604 in California |

Selective fat targeting: Some evidence suggests AOD 9604 preferentially targets visceral fat (the dangerous fat around your organs) over subcutaneous fat (under your skin)

Earlier oral trial METAOD005 randomized 300 adults with obesity to oral AOD-9604 (1, 5, 10, 20, or 30 mg/day) or placebo for 12 weeks

DEXA is most accurate but least accessible

Realistic expectations: Successful candidates understand that AOD-9604 is an adjunct to comprehensive lifestyle modification, not a standalone solution

If single morning administration produces satisfactory results, adding complexity provides no advantage

These established short-term safety and pharmacology context but were not designed to demonstrate weight loss efficacy